GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Cyclically Adjusted FCF per Share

Accelerate Diagnostics (STU:1A80) Cyclically Adjusted FCF per Share : €-9.56 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Accelerate Diagnostics's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.429. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-9.56 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -10.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -14.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Accelerate Diagnostics was -6.80% per year. The lowest was -177.60% per year. And the median was -20.20% per year.

As of today (2024-06-06), Accelerate Diagnostics's current stock price is €1.07. Accelerate Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-9.56. Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF of today is .


Accelerate Diagnostics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Accelerate Diagnostics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Cyclically Adjusted FCF per Share Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.96 -5.97 -7.52 -8.26 -9.56

Accelerate Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.81 -8.11 -8.86 -9.56 -9.56

Competitive Comparison of Accelerate Diagnostics's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF falls into.



Accelerate Diagnostics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Accelerate Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.429/131.7762*131.7762
=-0.429

Current CPI (Mar. 2024) = 131.7762.

Accelerate Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.751 100.560 -0.984
201409 -1.187 100.428 -1.558
201412 -0.975 99.070 -1.297
201503 -1.689 99.621 -2.234
201506 -2.065 100.684 -2.703
201509 -1.856 100.392 -2.436
201512 -2.188 99.792 -2.889
201603 -2.611 100.470 -3.425
201606 -2.657 101.688 -3.443
201609 -2.215 101.861 -2.866
201612 -2.378 101.863 -3.076
201703 -2.829 102.862 -3.624
201706 -2.332 103.349 -2.973
201709 -2.247 104.136 -2.843
201712 -2.157 104.011 -2.733
201803 -2.531 105.290 -3.168
201806 -2.973 106.317 -3.685
201809 -2.873 106.507 -3.555
201812 -2.349 105.998 -2.920
201903 -3.183 107.251 -3.911
201906 -2.290 108.070 -2.792
201909 -2.903 108.329 -3.531
201912 -2.313 108.420 -2.811
202003 -2.976 108.902 -3.601
202006 -1.602 108.767 -1.941
202009 -2.008 109.815 -2.410
202012 -1.486 109.897 -1.782
202103 -1.920 111.754 -2.264
202106 -1.299 114.631 -1.493
202109 -1.730 115.734 -1.970
202112 -1.598 117.630 -1.790
202203 -1.749 121.301 -1.900
202206 -1.613 125.017 -1.700
202209 -1.575 125.227 -1.657
202212 -0.935 125.222 -0.984
202303 -1.271 127.348 -1.315
202306 -0.920 128.729 -0.942
202309 -0.580 129.860 -0.589
202312 -0.495 129.419 -0.504
202403 -0.429 131.776 -0.429

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Accelerate Diagnostics  (STU:1A80) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Accelerate Diagnostics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (STU:1A80) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines